Zanzalintinib

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Aggressive Variant Prostate Carcinoma

Conditions

Aggressive Variant Prostate Carcinoma

Trial Timeline

May 1, 2026 → Dec 1, 2027

NCT ID

NCT07218666

About Zanzalintinib

Zanzalintinib is a phase 2 stage product being developed by Exelixis for Aggressive Variant Prostate Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218666. Target conditions include Aggressive Variant Prostate Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07218666	Phase 2	Recruiting	May 1, 2026	Dec 1, 2027	Aggressive Variant Prostate Carcinoma
NCT07428616	Phase 2	Recruiting	May 1, 2026	Sep 1, 2029	Meningioma
NCT07185945	Phase 2	Recruiting	Feb 1, 2026	Mar 1, 2029	Advanced Urothelial Carcinoma
NCT06926634	Phase 2	Recruiting	Dec 9, 2025	Dec 31, 2034	High Grade Neuroendocrine Neoplasms
NCT07193550	Phase 2	Recruiting	Dec 5, 2025	Oct 31, 2031	Bone Sarcomas
NCT06959511	Phase 2	Recruiting	Jul 22, 2025	Oct 1, 2030	Neoadjuvant Treatment
NCT06962332	Phase 1	Recruiting	May 13, 2025	Apr 1, 2026	Hepatic Impairment

Competing Products

11 competing products in Aggressive Variant Prostate Carcinoma

See all competitors

Product	Company	Stage	Hype Score
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy	Johnson & Johnson	Phase 2	52
Loncastuximab Tesirine and Epcoritamab	AbbVie	Phase 2	52
Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib	AstraZeneca	Phase 2	52
Midostaurin	Novartis	Phase 2	52
Imatinib	Novartis	Phase 2	52
Bendamustine and subcutaneous rituximab	Roche	Phase 2	52
Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate	Bristol Myers Squibb	Phase 1/2	40
Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate	Bristol Myers Squibb	Phase 2	51
Vandetanib 300 mg	Sanofi	Pre-clinical	22
cemiplimab + odronextamab	Regeneron Pharmaceuticals	Phase 1	32
PRT2527 + Zanubrutinib + Venetoclax	Prelude Therapeutics	Phase 1	25

Other Products from Exelixis

Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsuleApproved

cabozantinib + prednisonePhase 3

Cabozantinib tablets + Everolimus (Afinitor) tabletsPhase 3

XL184 + PlaceboPhase 3

XL092 + Atezolizumab + RegorafenibPhase 3